Teva Reinforces Leadership Position in Respiratory with Acquisition of Gecko Health Innovations

Article

Teva and Gecko Health Innovations have entered into a definitive agreement in which Teva will acquire Gecko Health Innovations.

PRESS RELEASE

JERUSALEM

&

CAMBRIDGE, Mass.

--(BUSINESS WIRE)--Sep. 25, 2015--

Teva Pharmaceutical Industries Ltd.

, (NYSE:TEVA) and

Gecko Health Innovations, Inc.

, a privately-held company focused on developing software and product solutions to aid in compliance and adherence improvement in the management of respiratory diseases, today announced that they have entered into a definitive agreement in which Teva will acquire Gecko Health Innovations.

“Teva is committed to optimizing respiratory care through the development of new therapies and novel delivery systems to better serve patients living with respiratory conditions,” said

Michael Hayden

, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva.

“The acquisition of Gecko Health Innovations further enhances Teva’s ability to develop and deliver truly patient-centered solutions by utilizing eConnected, data-driven technology to improve the management of respiratory diseases,” said Rob Koremans, M.D., President and CEO of Teva Global Specialty Medicines.

Through the agreement, Teva will acquire CareTRx, a novel cloud-based solution developed by Gecko Health Innovations, designed to simplify chronic respiratory disease management, connecting patients and caregivers through remote monitoring and real-time adherence tools. Together with Gecko Health Innovations founders,

Mark Maalouf

and Dr.

Yechiel Engelhard

, Teva will explore innovative ways to apply the CareTRx technology to its robust pipeline and portfolio of respiratory products with the goal of enhancing clinical outcomes for patients. CareTRx is a solution comprised of a hardware device which attaches to most metered-dose inhalers (MDIs) as well as a software program which synchronizes and stores data through an app-based user interface.

“During the last three years, we have designed and built a system to support respiratory disease management by intuitively connecting caregivers, patients, and families,” said Dr.

Yechiel Engelhard

, CEO and Founder of Gecko Health Innovations. “In founding

Gecko Health

Innovations, our vision was to connect chronic medication management into one platform, leveraging this information to support and empower patients by partnering with leading players in the healthcare and pharmaceutical industries. We are very excited to realize this vision as it aligns to Teva’s focus on innovative patient solutions.”

Related Videos
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit:  JPC-PROD | stock.adobe.com - Choosing method of contraception : Birth control pills, an injection syringe, condom, IUD-method, on grey
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.